Salute e Benessere

New National Survey of Healthcare Providers Offers Insights Into the Dynamic and…

DUBLIN, March 27, 2025 /PRNewswire/ -- People living with schizophrenia or bipolar I disorder (BDI) often face long and complex diagnostic and treatment journeys. Results from a newly completed survey designed to better understand the perspectives of healthcare providers on patients' treatment experiences and outcomes indicated that providers often prioritize approaches that support long-term symptom control, treatment consistency and quality of life considerations. This research was conducted…

Immatics Announces Full Year 2024 Financial Results and Business Update

Randomized-controlled Phase 3 trial, SUPRAME, to evaluate ACTengine® IMA203 TCR-T (PRAME) in advanced melanoma patients; first patient randomized and enrollment continues as plannedACTengine® IMA203 TCR-T (PRAME): Phase 1b IMA203 data published in October 2024 demonstrated a confirmed ORR of 54%, 12.1 months mDOR, 6 months mPFS and OS not reached at a mFU time of 8.6 months in advanced melanoma patients; next data update on Phase 1b trial with extended follow-up planned in 2025 ...

Beyonttra™ (acoramidis), the First Near-complete TTR Stabilizer (≥90%), Approved…

In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-toleratedThe approval was based on a Japanese Phase 3 study and the global ATTRibute-CM Phase 3 trial, which demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date. Key data from the ATTRibute-CM study include:In as few as 3 months, the time to first event (all-cause mortality (ACM) or cardiovascular-related hospitalization (CVH)) durably...

Medical Tubing Market worth $18.41 billion by 2030 - Exclusive Report by…

270 – Tables45 – Figures 275 – Pages 270 – Tables 45 – Figures275 – Pages Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=162082103 The market for medical tubing is growing based on a number of driving factors that are built on healthcare progress and trends. One of these is the increasingly ageing world population, which compels the need for tubing in the form of equipment such as catheters, IV tubes, and feeding tubes based on the reason that...

Zelluna ASA [ZLNA]: Share capital increase registered

Reference is made to the stock exchange notice published on 26 March 2025 regarding the resolution of the board of directors of Zelluna ASA (the " Company ") to carry out a share capital increase of NOK 0.70 through the issuance of seven (7) new shares, each with a par value of NOK 0.10. The share capital increase has today been registered with the Norwegian Register of Business Enterprises. After the share capital increase, the new share capital of the Company is NOK 20,227,066…

Hurom Juicers Earn Top Ratings from Germany's Haus & Garten Test Magazine

A trusted resource for consumers, Haus & Garten Test provides expert reviews to guide purchasing decisions. The publication awarded first place to Hurom's H310A and H320N which received high marks in every category including usability, build quality, and safety. A trusted resource for consumers, Haus &Garten Test provides expert reviews to guide purchasing decisions. The publication awarded first place to Hurom's H310A and H320N which received high marks in every category including...

Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer

Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the appointment of Dr. Balaji V. Prasad as Chief Strategy Officer.A medical doctor by training, Dr. Prasad has 25 years' experience in the pharmaceutical industry, first as a consultant and subsequently as a financial and equities analyst focused on the specialty pharma and healthcare sectors. He was most recently...

Alys Pharmaceuticals Announces Dosing of First Patient in Phase IIa Trial of…

Craig Mello, PhD, 2006 Nobel Prize in Physiology or Medicine Laureate, the Blais University Chair in Molecular Medicine and distinguished Professor of RNA therapeutics at UMass Chan Medical School, said:"It is exciting to see siRNA from our unique platform at the RNA Therapeutic Institute at UMass Chan Medical School, being deployed to yet another new organ system. Thanks to the unique accessibility of skin, we believe siRNA can result in a step change innovation in dermatological…

ILM-Blue from DORC Receives NMPA Approval in China; Expanding Global Reach

"We are delighted to bring ILM-Blue to the Chinese market, where it will provide retina surgeons with a proven, high-quality staining solution to enhance visualization," says Jessie Jiang Bo, General Manager of DORC in China. "This approval reinforces our dedication to expanding access to innovative ophthalmic solutions that help surgeons to improve patient outcomes." "We are delighted to bring ILM-Blue to the Chinese market, where it will provide retina surgeons with a…

Supporting modern cooking trends, Nestlé expands the Maggi Air Fryer Range in…

At the same time, Nestlé is also building out its Maggi Air Fryer series in Malaysia, where 42% of households own an air fryer.[3] Here, the company has introduced a Satay variant along with repositioning its existing marinade mixes as part of the air fryer series to provide consumers with an authentic taste from fresh ingredients in two simple steps – marinating and air frying. At the same time, Nestlé is also building out itsMaggiAir Fryer series inMalaysia, where 42% of households own...

CROSSJECT reports financial results for 2024

Press ReleaseCROSSJECT reports financial results for 2024Continued satisfactory production of regulatory batches with a view to filing in Q2 2025.Recruitment of Tony Tipton as Chief Operating Officer USA.Visibility gained on pipeline programs developed in collaboration with Eton Pharmaceuticals, Inc (Eton).Cash position increasing significantly to 7 million euros as of December 31, 2024.Dijon, France, March 27, 2025 (07.30 CET) – CROSSJECT (ISIN : FR0011716265 ; Euronext :...

Santhera proposes Dr. Melanie Rolli as new member of Board of Directors

Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, March 27, 2025–Santhera Pharmaceuticals (SIX: SANN) proposes to elect Dr. Melanie Rolli as an Independent Director at the upcomingAnnual General Meeting to be held on May 20, 2025. Current Board member Dr. Otto Schwarz will not stand for re-election.Thomas Meier, Chairman of the Board of Directors of Santhera, said:"We are delighted Dr. Rolli has agreed to be nominated to join the Board; where we believe she would...

Press release: Sequana Medical to Attend the “VFB Happening 2025” in Ghent…

Sequana Medical to Attend the “VFB Happening 2025”in Ghent, Belgium on Saturday, 29 March 2025 Ghent, Belgium – 27 March 2025 – Sequana Medical NV (Euronext Brussels: SEQUA, the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, is pleased to announce its participation in the “VFB Happening 2025” this Saturday, 29 March 2025, in the Congress Center ICC in Ghent. As Belgium's most…

Idorsia publishes its Annual Report 2024

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – March 27, 2025Idorsia Ltd (SIX: IDIA) today announced the publication of the Annual Report 2024 – consisting of the Business Report, Governance Report, Compensation Report, Sustainability Report, and Financial Report (already published on March 4, 2025).All five books of the Annual Report 2024 are available atwww.idorsia.com/annual-report. Note to ShareholdersThe Annual General Meeting (AGM) of Shareholders to...

Junshi Biosciences Announces Toripalimab's Approval in Singapore

NPC is a malignant tumor that occurs in the epithelium mucosae of the nasopharynx and is one of the most common types of head and neck cancers. According to GLOBOCAN 2022 statistics, the number of newly diagnosed NPC cases in 2022 exceeded 120,000 worldwide. Toripalimab is the only preferred regimen recommended for the comprehensive treatment of recurrent or metastatic NPC in the National Comprehensive Cancer Network (NCCN) Guidelines (Version 1.2025) for head and neck cancers.The approval...

Alvotech Reports Record Results for 2024 and Provides Business Update

Total Revenues in 2024 reached $492 million, representing a 427% increase over prior yearProduct Revenues in 2024 reached $273 million, representing a 462% increase over prior yearAdjusted EBITDA in 2024 was $108.3 million compared to negative $291 million in 2023Submissions in major global markets were made in 2024 for three new proposed biosimilars. All applications have been subsequently accepted by the relevant regulatory authorities. Alvotech will conduct a...

VUITY Reports Strong Market Performance, Setting New Benchmark in Presbyopia…

AbbVie's VUITY (pilocarpine hydrochloride ophthalmic solution) Overview AbbVie's VUITY (pilocarpine hydrochloride ophthalmic solution) Overview VUITY, developed by Allergan (now part of AbbVie), is a 1.25% pilocarpine hydrochloride ophthalmic solution designed to treat presbyopia in adults. It acts as a cholinergic muscarinic receptor agonist and comes as a sterile, isotonic, colorless solution. The active ingredient, pilocarpine hydrochloride, stimulates muscarinic receptors in smooth...

LUXTURNA Continues to Lead in Retinal Gene Therapy with Increased Market…

Spark Therapeutics/Novartis' LUXTURNA (AAV2-hRPE65v2; voretigene neparvovec) Overview Spark Therapeutics/Novartis' LUXTURNA (AAV2-hRPE65v2; voretigene neparvovec) Overview LUXTURNA (voretigene neparvovec-rzyl, AAV2-hRPE65v2) is a one-time gene therapy designed to treat vision loss caused by mutations in both copies of the RPE65 gene. It works by delivering a functional copy of the RPE65 gene to replace the faulty one, helping to restore vision. The therapy is administered as a single...

Jazz Pharmaceuticals to Participate in the 24th Annual Needham Virtual…

About Jazz PharmaceuticalsJazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and…

Inventiva reports its 2024 full year results and provides a business update

Revenues of €9.2 million for the full year of 2024Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 million Structured Financing closed with aggregate gross proceeds of €116 millionLast patient screened in the NATiV3 Phase 3 clinical trial of lanifibranor in MASH early in January 2025 Pipeline prioritization plan presented to the workers council to focus exclusively on the development of lanifibranor, stopping all preclinical research...

Global Surgical Equipment Market Expected to Reach USD 56.6 Billion by 2029

The report examines the leading companies, technology trends, market dynamics, and regional trends in the surgical equipment market. The report also examines the impact of COVID-19 on the market and the supply chain, taking into consideration economic factors such as healthcare spending and medical tourism. It covers the use of emerging technologies such as AI and machine learning in surgeries. The market is segmented by usability (disposable and reusable), product category, technology, end user…

OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides…

OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate UpdateTotal income of €83.4 million. Cash level of €64.2 million 1as of December 31, 2024, ensuring financial visibility until Q1 2027Three strategic agreements signed: licensing and collaboration with AbbVie (worth up to $713 million), and anti-SIRP αprogram expansions (worth up to€ 1.1 billion), plus a purchase asset agreement with Boehringer Ingelheim.€ 8.4 million in non-dilutive...

Valneva Renews its Sales Agreement in connection with its Existing At-the-Market…

Saint-Herblain (France), March 26, 2025– Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (“ Valneva ” or the “ Company ”), a specialty vaccine company, today announces that it has filed a prospectus supplement as part of the renewal of its registration statement on Form F-3, filed on March 25, 2025 with the U.S. Securities and Exchange Commission (“SEC”) relating to its existing At-the-Market offering facility (the “ATM Program”), which was originally entered into in August 2022 and has not...

GUERBET : 2024 full-year results.

2024 full-year results Very strong business momentumFull-year revenue: €841.1 million, up 9.0% at constant exchange rates (CER) 1and on a like-for-like basis 2 Strong momentum in the Americas (+20.5% at CER and like-for-like), Asia (+10.1%) and EMEA excluding France (+8.8%)Solid increase in profitabilityRestated EBITDA margin 3of 14.9%, versus 13.1% a year earlierOperating income up 28.2% to €49.6 million2025 targetsFurther growth in profitability: restated...

Altri Comunicati